Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study

BACKGROUND: We evaluated our SARS-CoV-2 prefusion spike recombinant protein vaccine (CoV2 preS dTM) with different adjuvants, unadjuvanted, and in a one-injection and two-injection dosing schedule in a previous phase 1–2 study. Based on interim results from that study, we selected a two-injection sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sridhar, Saranya, Joaquin, Arnel, Bonaparte, Matthew I, Bueso, Agustin, Chabanon, Anne-Laure, Chen, Aiying, Chicz, Roman M, Diemert, David, Essink, Brandon J, Fu, Bo, Grunenberg, Nicole A, Janosczyk, Helene, Keefer, Michael C, Rivera M, Doris M, Meng, Ya, Michael, Nelson L, Munsiff, Sonal S, Ogbuagu, Onyema, Raabe, Vanessa N, Severance, Randall, Rivas, Enrique, Romanyak, Natalya, Rouphael, Nadine G, Schuerman, Lode, Sher, Lawrence D, Walsh, Stephen R, White, Judith, von Barbier, Dalia, de Bruyn, Guy, Canter, Richard, Grillet, Marie-Helene, Keshtkar-Jahromi, Maryam, Koutsoukos, Marguerite, Lopez, Denise, Masotti, Roger, Mendoza, Sandra, Moreau, Catherine, Ceregido, Maria Angeles, Ramirez, Shelly, Said, Ansoyta, Tavares-Da-Silva, Fernanda, Shi, Jiayuan, Tong, Tina, Treanor, John, Diazgranados, Carlos A, Savarino, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789245/
https://www.ncbi.nlm.nih.gov/pubmed/35090638
http://dx.doi.org/10.1016/S1473-3099(21)00764-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789245/
https://www.ncbi.nlm.nih.gov/pubmed/35090638
http://dx.doi.org/10.1016/S1473-3099(21)00764-7

Ejemplares similares